Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Primary Immune Thrombocytopenia
NCT06199089Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in primary immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2024; status: active, not recruiting.
02
Drugs
cm313
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06199089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199089.